115 0 obj <> endobj Abbott et al (2012) ... A 2-dose rotavirus vaccine was used by 22 studies and a 3-dose vaccine by 7 studies. %%EOF Two major active (67) and passive (68,69) surveillance systems monitoring vaccine safety in the United States have detected substantial rates of missing and erroneous data (greater than or equal to 10%) in the recording of vaccine type, brand, or lot number in the medical records of vaccine recipients (CDC, unpublished data, 1997). However, rotavirus vaccine coverage has remained relatively low (70–75%) compared to … endstream endobj 116 0 obj <>/Metadata 11 0 R/OpenAction 117 0 R/PageLayout/OneColumn/Pages 113 0 R/StructTreeRoot 33 0 R/Type/Catalog>> endobj 117 0 obj <> endobj 118 0 obj <>/MediaBox[0 0 612 792]/Parent 113 0 R/Resources<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 119 0 obj <>stream Rotavirus is the leading cause of severe acute gastroenteritis in infants and young children worldwide, causing about 453 000 child deaths every year before the introduction of the rotavirus vaccine.
Abbott C, Tiede B, Armah G, Mahmoud A. There is a growing interest in the possible relationship between rotavirus (RV) vaccine and hospitalizations due to childhood seizures. 154 0 obj <>stream C. Abbott, et al.Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana Vaccine, 30 (15) (2012), pp. 2012;30(15):2582–2587. Offitt, a professor of pediatrics at the Children’s Hospital of Philadelphia, worked for 25 years on the rotavirus vaccine. Vaccine 2012; 30 :2582–7. h�bbd```b``z"��H;��Z)�"�#@$��ds ��`6+���, �)�,/��$����$S�T �X2$b�b�7�I R�0���4 �f�^F*���f~0 �)d h�ko]7v����%�4�`��ͤ�d�8m 2012 Mar [cited 2019 Apr 3];30(15):2582–7.
Rotavirus infection is thought to be a risk factor for type 1 diabetes mellitus (T1DM). Abbott C, Tiede B, Armah G, and Mahmoud A. %PDF-1.7 %���� finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Introduction. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. h�b``�```������o� Ā B@1V �8������$�(*vl����& �'ۢ -Ģ`�dA���?�-����Bh We explored variation in hospitalization rates after 9 years of vaccination against pre-vaccination period for children <5 years of age from Galicia (Northwest Spain) before and after the introduction of the RV vaccines. 2582-2587 Google Scholar 2013;31(42):4902–4910. Fill in a product description parameter value(s), if you would like to display only vaccines with matching values.
Polio Vaccine - Oral (OPV) Bivalent Types 1 and 3: Poliomyelitis Vaccine (Oral), Bivalent types 1 and 3: Liquid: ready to use: Vial: 10: Serum Institute of India Pvt. 12. �+Ӽ�憂,���z�d���/b���{�F.��@�00�ހ����m�_�(�� ��"� [ … Vaccine. endstream endobj startxref Define date range or either one of these dates if you would like to display only prequalified vaccines within a certain period. Abbott C, Tiede B, Armah G, Mahmoud A.
Offit spent 26 years developing a vaccine for rotavirus, a common and dangerous childhood gastrointestinal illness, before it was approved by the Food and Drug Administration in 2006.
0
11. 138 0 obj <>/Filter/FlateDecode/ID[<09C099EE161B354CAF52D2D0B516EC09><43E641AECFD20B4DA3EB0B9223F12B04>]/Index[115 40]/Info 114 0 R/Length 117/Prev 440569/Root 116 0 R/Size 155/Type/XRef/W[1 3 1]>>stream Abbott Laboratories: Compositions and methods of use for a major outer capsid protein (vp7) of rotavirus sa-11 US4927628A (en) * 1987-09-21: 1990-05-22: The United States Of America As Represented By The Department Of Health And Human Services: Vaccine against rotavirus diseases and method of preparing same l�J�:l9��i���>��9[�|KQ���"���u�>��;��1���VT��*���V�'�uղj�S��A}�ov�n�g�I�hU�����'{�G{���m�v��/>����/�_>����_�.����/�o/o�.~���y��'~x����_��J��������^]?���PJ���j��$��W�.��:���^��~�ً߶Ori:�Mw4�W�ϯ������ϯ^�����w/�_�|a������O?�m�釁`r�����g�?=�y����.�^=��Csc���^^�r�����u��l>�|uE��_Ͷ��J�}}��/�lw�������o.�X�}��,��{��c���-�h,=@-���as[����"�Ci�-ƨյc9�C�ζ���^�����o�7��$He����!4����v�^]�wL[��5�c���t�*���C�;r.G��(��4���V���Q4�Ғ�������QE��C�zJ����96�1���E�n8[]Rߗj?��l-U��6�6��j�MȍA-��fWZ;���X�{m�h��%�9��ʜ�Qװ�%�7Vƪ��w����>~���{{����3��~�}���ln��{6X��hU�}��Q����p�I���n�����g�"xKv��-�'��&^,hӂڣg��Q���h"��3�Ň��Y�:�»��ּ-ox`sy��o�6�;-Ǝ����>���|H��A7��^����0�˻�>�t;���n��'�L"8�\B���m?��t�Ck��ɂ0�VY�>� Kwʒ����]�췳[���^��v���U��~�'����{o�rAwb#9�T�i��'I�렩\�ߺ��cJe��p��/E߷^'io��dǨ�c��M)\E{Չ?�(:�{����j���_4��鹔��}=��j��Rlb¾��P�� �7� Background Prior to vaccine introduction in 2006, rotavirus was the leading cause of severe diarrhea in children under five years of age in the U.S. Vaccination of infants has led to major reductions in disease burden, a shift in the seasonal peak and the emergence of a biennial pattern of disease. Vaccine. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. Vaccine [Internet]. Define your filter criteria by clicking select and select item(s) from the dialog box that will appear and then click Add. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.